The S&P500 (SP500) closed in the green on Friday, with companies including Walmart, Nvidia and Gap stealing the limelight ...

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second ...

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...